Inhibiting effects of Oxymatrine on hepatic stellate cells activation through regulating miR-195 in

来源 :2017年中国药学大会暨第十七届中国药师周 | 被引量 : 0次 | 上传用户:xinran200391127
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Aim:Oxymatrine(OM)is a monomer extracted from Sophora species that has been used to treat fibrotic diseases.While its anti-fibrotic potential in clinical application is limited due to a lack of specific mechanism,so our study aim to explore the molecular mechanism of inhibitory effect of Oxymatrine on HSCs activation and and its modulation on the TGF-β/Smad signaling pathway.METHODS:HSC-T6 was cultivated for our study,the effect of different concentrations and time of OM on HSC-T6 cell viability was determined by MTT assay.Then groups were divided as follows,(1)Control group,(2)TGF-β1 group,(3)125 μg/mL OM+TGF-β1 group,(4)250 μg/mL OM+TGF-β1 group,(5)500 μg/mL OM+TGF-β1 group,(6)IFN-γ+TGF-β1 group,(7)miR-195 mimic+OM+TGF-β1 group,(8)miR-195 mimic control+OM+TGF-β1 group.HSC-T6 were respectively transfected 100 nM miR-195 mimic/mimic control and incubated for 24 h,then the drug treatment group was treated with 250 μg/mL OM for 1 h,while the positive drug group was treated with 500 U/mL IFN-γ for 1 h,at last added 5 ng/mL TGF-β1 to the cells,cultured for 24 h.The mRNA expression of miR-195,Smad7 and HSC-T6 activation marker gene α-SMA were detected by Quantitative Real-time PCR.The protein expression of α-SMA were detected by Western Blot.Results:Inhibition effect of OM on HSC-T6 cell proliferation was strengthened along with the elevated concentrations and prolonged incubation time.OM could decrease cell activation induced by TGF-β1 in a dose-dependent method,reduce the expression of miR-195 and α-SMA(P<0.01),and promote the expression of Smad7(P<0.05).OM and IFN-γ had similar anti-activation effect on HSC-T6.HSC-T6 transfected with miR-195 mimic and pretreated OM could upregulate the expression of miR-195 and α-SMA(P<0.05),and downregulate the expression of Smad7(P<0.05)compared with the OM group.Conclusions:OM could attenuate HSCs activation induced by TGF-β1 in a dose-dependent method,which achieved via down-regulating the expression of miR-195 and up-regulating Smad7 which is the target of miR-195.
其他文献
在数千年的发展过程中,中医药不断吸收和融合各个时期先进的科学技术和人文思想,不断创新发展,理论体系日趋完善,技术方法 更加丰富,从文献理论-临床实践-复方新药的相互转化形成了自身鲜明的特点.第一,个体重视整体,群体则强调个体化.中医认为人与自然、人与社会是一个相互联系、不可分割的统一体,人体内部也是一个有机的整体.重视自然环境和社会环境对健康与疾病的影响,认为精神与形体密不可分,强调生理和心理的协
A key challenge for the use of inorganic nanomedicines in clinical applications is their long-term accumulation in internal organs,which raises the common concern of the risk of adverse effects and in
目的:考察阿胶对大肠杆菌生长代谢的影响,评价阿胶类中药的生物活性,为其质量控制提供研究基础,为阿胶的生物评价模式构建新的方法 .方法:应用生物热动力学—微量量热法,进行阿胶对生物模型的热活性影响的研究.以对数生长期与指数生长期最大产热功率的变化作为对大肠杆菌生长代谢的客观观察指标.根据分析不同给药剂量间的指标差异,选择合适的剂量作为评价指标.结果:与对照组相比,阿胶在5mg/ml—30mg/ml
Background:Liuweiwuling(LWWL)tablets are an herbal product that exert remarkable effects on liver protection and aminotransferase levels and have been approved by the Chinese State Food and Drug Admin
目的:利用重组聚合酶扩增(RPA)建立一种快速鉴定草药营养产品中植物物种的方法 。方法:利用银杏和槐在ITS2 及rbcL 区域内的特异性短序列来建立RPA 试验,并根据物种特异性序列来设计用于RPA 试验的引物和探针。首先,在网上购买了36 份银杏草药产品,并进行DNA 提取。通过聚合酶链式反应(PCR)和焦磷酸测序确认从银杏草药产品中提取的DNA 中存在银杏以及槐的物种特异性序列。最后,利用R
目的:为了发挥栓塞治疗与药物化疗的双重功效,同时能够利用MRI 监测栓塞进程及效果,我们制备了包载舒尼替尼和磁性氧化铁纳米簇的MRI"可视化" 载药栓塞微球,并对其进行了体外的初步评价.方法:前期我们采用微波辅助溶剂热法制备了磁性氧化铁纳米簇,将其作为MRI 显影材料包载到聚丙烯酸微球中;并考察了该微球的理化性质、栓塞性质和MRI 可视性.本研究进一步将化疗药物舒尼替尼载入该微球,制备了同时包载舒
目的:Apelin 作为APJ 的内源性配体,apelin/APJ 系统在心脑血管疾病中起着重要的作用.本课题组前期报道apelin-13 可通过PI3K-Akt、ERK1/2、14-3-3、NOX4\ROS、Notch3 途径促血管平滑肌细胞增殖,参与动脉粥样硬化的形成.文献报道细胞迁移也可参与动脉粥样硬化形成,本课题旨在探讨apelin-13 对人主动脉血管平滑肌细胞迁移的作用,深入讨论NCS
脑胶质瘤占原发脑肿瘤近50%,临床治疗难度大、危害性大.98%小分子药物和近100%大分子药物难以入脑的原因在于,脑胶质瘤存在复杂的生物屏障系统,即:脑胶质瘤早期和肿瘤细胞浸润区存在血-脑屏障(BBB),肿瘤新生血管形成后又出现血-脑肿瘤屏障(BBTB),后续出现的EPR 效应也比外周肿瘤弱的多,脑胶质瘤细胞还可变异形成拟态血管引流血液营养自身,除胶质瘤细胞外还存在胶质瘤干细胞等.为此,我们针对脑
会议
目的:评价2012 至2016 年西安地区三级医院抗菌药物管理工作,为医院抗菌药物科学管理提供依据.探讨TOPSIS 综合评价法在抗菌药物管理评价中的应用.方法:采用TOPSIS 综合评价法,选取8 项抗菌药物管理指标对西安地区10 家三级医院的抗菌药物管理效果作出评价.结果:通过TOPSIS 综合排序得5 年间的管理效果排名情况,2012最差(Ci=0.0000),2012 至2014 年逐步提
During manufacturing and storage process,therapeutic proteins are subject to various post-translational modifications(PTMs),such as isomerization,deamidation,oxidation,disulfide bond modifications and